Page last updated: 2024-08-17

lysine and avapro

lysine has been researched along with avapro in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	2 (50.00)	2.80

Authors

Authors	Studies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Busch, M; Franke, S; Rohde, RD; Stein, G; Wolf, G	1
Engelen, L; Ferreira, I; Hovind, P; Parving, HH; Persson, F; Rossing, P; Schalkwijk, CG; Stehouwer, CD; Teerlink, T	1
Daugherty, A; Franklin, MK; Howatt, DA; Lu, HS; Moorleghen, JJ; Mullick, AE; Ohno-Urabe, S; Sawada, H; Ye, D	1

Trials

2 trial(s) available for lysine and avapro

Article	Year
Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron. Clinical practice, 2008, Volume: 108, Issue:4 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Biphenyl Compounds; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Glomerular Filtration Rate; Glycation End Products, Advanced; Humans; Hypertension; Irbesartan; Linear Models; Lysine; Male; Middle Aged; Statistics, Nonparametric; Tetrazoles	2008
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:11 Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycation End Products, Advanced; Humans; Hypertension; Irbesartan; Lysine; Male; Middle Aged; Prognosis; Tetrazoles	2011

Article

Year

Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.

Nephron. Clinical practice, 2008, Volume: 108, Issue:4

Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Biphenyl Compounds; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Glomerular Filtration Rate; Glycation End Products, Advanced; Humans; Hypertension; Irbesartan; Linear Models; Lysine; Male; Middle Aged; Statistics, Nonparametric; Tetrazoles

2008

Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:11

Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycation End Products, Advanced; Humans; Hypertension; Irbesartan; Lysine; Male; Middle Aged; Prognosis; Tetrazoles

2011

Other Studies

2 other study(ies) available for lysine and avapro

Article	Year
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Inhibition of the Renin-Angiotensin System Fails to Suppress β-Aminopropionitrile-Induced Thoracic Aortopathy in Mice-Brief Report. Arteriosclerosis, thrombosis, and vascular biology, 2022, Volume: 42, Issue:10 Topics: Aminopropionitrile; Angiotensin II; Angiotensinogen; Animals; Aortic Aneurysm, Thoracic; Aortic Rupture; Dilatation, Pathologic; Disease Models, Animal; Irbesartan; Losartan; Lysine; Male; Mice; Mice, Inbred C57BL; Protein-Lysine 6-Oxidase; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System	2022

Article

Year

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.

Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023

Inhibition of the Renin-Angiotensin System Fails to Suppress β-Aminopropionitrile-Induced Thoracic Aortopathy in Mice-Brief Report.

Arteriosclerosis, thrombosis, and vascular biology, 2022, Volume: 42, Issue:10

Topics: Aminopropionitrile; Angiotensin II; Angiotensinogen; Animals; Aortic Aneurysm, Thoracic; Aortic Rupture; Dilatation, Pathologic; Disease Models, Animal; Irbesartan; Losartan; Lysine; Male; Mice; Mice, Inbred C57BL; Protein-Lysine 6-Oxidase; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System

2022